A decade of hair-loss clinical trials: a registry-based analysis of studies registered on ClinicalTrials.gov
By
Alexa D. Parra-Guerra
Luis E. Sánchez-Dueñas
Mariana León Quintero-Loreto
Deyanira G. Quinoñes-Hernández
Jessica A. Moreno-Alanis
Farah K. Sevilla González
Cesar J. Ramos Cavazos
Daniela Gutiérrez Mendoza
César D. Villarreal-Villarreal
Jonathan M. Chejfec-Ciociano
June 22, 2026
Clinical Scorecard: Ten Years of Clinical Trials on Hair Loss: An Analysis of Studies Documented in the ClinicalTrials.gov Registry
At a Glance
Category Detail
Condition Hair Loss Disorders Key Mechanisms Androgenetic alopecia and alopecia areata with diverse therapeutic approaches. Target Population Individuals experiencing hair loss, including those with androgenetic alopecia and alopecia areata. Care Setting Clinical research and trials
Key Highlights
514 hair-loss trials identified, with increasing registrations post-2020. Pharmacologic therapies are the most common interventions. Geographic concentration of trials, particularly in North America. Heterogeneity in outcome reporting and assessment methods. Emerging therapies include Janus kinase inhibitors and novel drug delivery systems. Guideline-Based Recommendations
Diagnosis
Hair-loss disorders should be diagnosed based on clinical evaluation and patient history. Management
Current management for AGA includes topical minoxidil and oral finasteride; AA management involves corticosteroids and systemic immunosuppressants. Monitoring & Follow-up
Patients should be monitored for treatment efficacy and HRQOL outcomes. Risks
Potential risks include treatment side effects and variability in individual response to therapies. Patient & Prescribing Data
Patients with androgenetic alopecia and alopecia areata.
Therapeutic diversity is increasing, with both traditional and novel treatment modalities being explored.
Clinical Best Practices
Standardization of outcome measures in clinical trials is recommended. Increased representation of diverse populations in research is necessary. Alignment of research investment with clinical needs should be prioritized. Related Resources & Content
